T
JAZZ icon

Tidemark’s Jazz Pharmaceuticals JAZZ Stock Holding History

Tidemark’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45K Hold
6
– – ﹤0.01% 718
2026
Q1 		$1.13K Hold
6
– – ﹤0.01% 689
2025
Q4 		$1.02K Hold
6
– – ﹤0.01% 610
2025
Q3 		$791 Hold
6
– – ﹤0.01% 644
2025
Q2 		$637 Hold
6
– – ﹤0.01% 665
2025
Q1 		$745 Buy
+6
New +$783 ﹤0.01% 660
2024
Q4 		– Sell
-6
Closed -$668 – 658
2024
Q3 		$668 Hold
6
– – ﹤0.01% 588
2024
Q2 		$640 Hold
6
– – ﹤0.01% 580
2024
Q1 		$723 Hold
6
– – ﹤0.01% 652
2023
Q4 		$738 Buy
+6
New +$749 ﹤0.01% 651

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Tidemark's JAZZ Position: Q2 2026 in Review

Tidemark held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 6 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #718.

Tidemark first reported a position in JAZZ in Q4 2023 and has held it in 10 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Tidemark held 6 shares of Jazz Pharmaceuticals worth $1.45K as of Q2 2026.
  • Tidemark left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Tidemark's portfolio in Q2 2026, its #718 holding.
  • Tidemark first reported a position in Jazz Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.